SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001829126-22-020168
Filing Date
2022-12-12
Accepted
2022-12-12 08:43:20
Documents
14
Period of Report
2022-12-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K titanpharma_8k.htm   iXBRL 8-K 38260
2 EXHIBIT 10.1 titanpharma_ex10-1.htm EX-10.1 291098
3 EXHIBIT 99.1 titanpharma_ex99-1.htm EX-99.1 9710
  Complete submission text file 0001829126-22-020168.txt   566037

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ttnp-20221206.xsd EX-101.SCH 3233
5 XBRL LABEL FILE ttnp-20221206_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ttnp-20221206_pre.xml EX-101.PRE 22363
8 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_8k_htm.xml XML 3626
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-13341 | Film No.: 221456286
SIC: 2836 Biological Products, (No Diagnostic Substances)